Andrea Georgiou

1 month ago | biorxiv.org | Andrea Georgiou |Panos Zanos |Anna Onisiforou

AbstractAlzheimer′s disease (AD) and Diabetes Mellitus Type II (DM2) share overlapping pathological mechanisms, with DM2 increasing AD risk. Disease-modifying therapies (DMTs) for DM2, including Metformin and Semaglutide, have been explored for neuroprotection, yet their efficacy in AD remains unclear.

Oct 6, 2023 | dovepress.com | Andrea Georgiou |Reshma Ramesh |Peter T Schofield |Patrick White

Andrea Georgiou, Reshma Ramesh, Peter Schofield, Patrick White, Timothy H Harries School of Population Health & Environmental Sciences, King’s College London, London, UK Correspondence: Timothy H Harries, King’s College London, Department of Population Health Sciences, School of Life Course & Population Sciences, King’s College London, 3rd Floor Addison House, Guys Campus, London, SE1 1UL, UK, Tel +44 20 7836 5454, Email [email protected] Background: Inhaled corticosteroid (ICS) therapy has...